Long-term studies and direct comparisons between various GLP-1 agonists should be given priority in future research to determine the best way to use them in the management of diabetic nephropathy and to pinpoint patient subgroups that might benefit the most. This evidence concerns the gene GCG and diabetic kidney disease.